Programme
THURSDAY, 2 NOVEMBER |
|
| 9:00 | Patient advocacy session: Direct patient involvement in ABC research (Chairs: Bertha Aguilar Lopez, MX - Anna Cabanes, US - Shirley A. Mertz, US) (Panellists: Bertha Aguilar Lopez, MX - Jonas Bergh, SE - Matthew J. Ellis, US - Shirley A. Mertz, US Danielle Spence AU - Nikhil Wagle, US) |
| 9:00 | Sponsored satellite symposium |
| 10:30 | Coffee break |
| 11:00 | Patient advocacy session: Survivorship 101: Work, finances, home and emotional support (Chairs: Gunes Kalkan, UK - Gertrude Nakigudde, UG and Evi Papadopoulos, CY) • How can I swim in a storm (Gertrude Nakigudde, UG) • Discussion • The support of the other side (Lesley Fallowfield, UK) • Discusssion • Work means more than money (Evi Papadopoulos, CY) • Discusssion |
| 11:00 | Sponsored satellite symposium |
| 12:30 | Lunch |
| 12:40 | UICC invites participants to Room 1.06 by the exhibition area to the event: Chance to meet SPARC MBC Challenge awardees |
| 14:00 | Opening session (Chairs: Fatima Cardoso, PT and Larry Norton, US) • Welcome to Lisbon (Prof. Marcelo Rebelo de Sousa, President of the Portuguese Republic) • Opening and introduction (Fatima Cardoso, PT) • Keynote lecture: Living two roles: oncologist and patient (Bella Kaufman, IL) |
| 15:00 | Long term remissions: Challenges and controversies (Chairs: Anna Cabanes, US and Olivia Pagani, CH) • Management issues: How and until when to treat? (Christoph Thomssen, DE) • Is family planning (fertility, adoption) out of the question? (Shani Paluch-Shimon, IL) • Impact on legal and professional lives (Elizabeth Bergsten Nordström, SE) • Discussion |
| 15:55 | Best abstract presentations (Chairs: Alberto Costa, IT/CH and Danielle Spence, AU) • Analysis of the gaps on metastatic breast cancer global policies and advocacy efforts to support policy development across the patient journey (Maia Thrift-Perry, US) • Impact of disease progression status on time to deterioration of patient reported health related quality of life in first line er+ her2-ve advanced/metastatic breast cancer patients in the PALOMA-2 study (Nadia Harbeck, DE) • Effect of exercise on cardiovascular fitness and quality of life outcomes in advanced breast cancer patients (E. Oliveira, PT) • Discussion |
| 16:35 | Coffee break |
| 17:00 | Optimizing anti-HER-2 therapies for ABC (Chairs: Elzbieta Senkus, PL and Eric P. Winer, US) • Optimal sequence with and without all availble agents (Ian E. Krop, US) • Overcoming resistance to anti-HER2 therapies (Karen Gelmon, CA) • Potential role of immunotherapy (Javier Cortés, ES) • Will biosimilars become standard? (Smruti Koppikar, IN) • Discussion |
| 18:00 | Patient advocacy session: Registries, databases and statistical modelling: making MBC count (Chairs: Musa Mayer, US and Danielle Spence, AU) • Introduction and Australia STAR project (Danielle Spence, AU) • Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States (Musa Mayer, US) • The new German Cancer Registry (Norbert Marschner, DE) • Breast Cancer Care UK (Gunes Kalkan, UK) • Discussion |
| 18:00 | Sponsored satellite symposium |
| 19:30 | Welcome cocktail |
FRIDAY, 3 NOVEMBER |
|
| 8:30 | The new management of luminal ABC (Chairs: Bertha Aguilar Lopez, MX and Binghe Xu, CN) • Best sequence of available therapies (Nadia Harbeck, DE) • Management of new side effects (Carlos H. Barrios, BR) • Mechanisms of resistance to endocrine and biological agents (Stephen R.D. Johnston, UK) • Discussion |
| 9:25 | ABC Award and Lecture (Chair: L. Norton, US; Awardee: M. Mayer, US) Silent voices speak: An advocate's journey |
| 9:45 | Coffee break |
| 10:20 | Clinical challenges (Chairs: Jonas Bergh, SE and Renate Haidinger, DE) • Metronomic chemotherapy: A good old friend (Nagi S. El Saghir, LB) • Maintenance therapy (CT, ET, biologics) (Prudence A. Francis, AU) • Oral drugs: Challenges for the oncology nurse (Christine B. Boers-Doets, NL) • ABC elderly patient management (Laura Biganzoli, IT) • Discussion |
| 11:30 | Inflammatory advanced breast cancer (Chairs: Maria João Cardoso, PT and Gertrude Nakigudde, UG) • Biology of inflammatory breast cancer (Frédérique Penault-Llorca, FR) • Extensive cutaneous metastases: A separate entity? (Giuseppe Curigliano, IT) • The role of different radiation techniques (Birgitte V. Offersen, DK) • Discussion |
| 12:25 | Lunch and poster session (details regarding posters are available at the bottom of this page) |
| 13:30 | Lost in translation! (Chairs: Dian “CJ” M. Corneliussen-James, US and Daniel A. Vorobiof, ZA) • Multigene testing: Aid or clinical nightmare (Fabrice André, FR ) • The role of ctDNA (Nicholas C. Turner, UK) • Precision/personalized medicine: Hopes & hypes (George W. Sledge, US) • Discussion |
| 14:25 | Supportive and palliative care (Chairs: Matti S. Aapro, CH and Musa Mayer, US) • Management of neurotoxicity (Matti S. Aapro, CH) • Peritoneal carcinomatosis and ascites: Best practices (Véronique Diéras, FR) • End-of-life communication: Patient and health care provider perspectives - Part I (Lesley Fallowfield, UK) - Part II (Musa Mayer, US) • Discussion |
| 15:35 | Coffee break |
| 16:00 | A world of contrasts! (Chairs: Fatima Cardoso, PT and Shirley A. Mertz, US) • Access to radiation worldwide (Mary K. Gospodarowicz, CA) • Shortage of drugs: Solutions (Alexandru Eniu, RO) • eHealth: Friend or foe (Timo Schinköthe, DE) • Discussion |
| 17:00 | Management of triple negative ABC (Chairs: Shinji Ohno, JP and E. Papadopoulos, CY) • What's new in biology (Aleix Prat, ES) • The role of immunotherapy (Hope S. Rugo, US) • New kids on the block: CDKi, ARi, PARPi (Lisa A. Carey, US) • Discussion |
| 18:00 | Patient advocacy session: ABC Advocacy: Managing side effects, sexual issues and fertility (Chairs: Dian “CJ” M. Corneliussen-James, US and Renate Haidinger, DE) • How can physicians help to avoid or treat side effects? (Christoph Thomssen, DE) • How can patients help to avoid or treat side effects? (Renate Haidinger, DE) • Discussion • Intimacy - Starting Anew (Dian “CJ” M. Corneliussen-James, US) • Fertility -The Joys and the Risks (Dian “CJ” M. Corneliussen-James, US) • Discussion |
| 18:00 | Sponsored satellite symposium |
SATURDAY, 4 NOVEMBER |
|
| 8:30 | Consensus session (part I) (ABC4 chairs, scientific committee members and panellists) |
| 10:30 | Coffee break |
| 11:00 | Report from ABC Patient Advocacy Committee (Danielle Spence, AU) |
| 11:15 | Consensus session (part II) (ABC4 chairs, scientific committee members and panellists) |
| 13:00 | Close |
A/V RECORDING DURING THE CONFERENCE IS PROHIBITED
SATURDAY, 4 NOVEMBER AND SUNDAY, 5 NOVEMBER 2017 |
|
|
|
ABC4 was followed by the first meeting of the ABC Global Alliance: |
Poster session
BP: Best poster presentation; PO: Poster presentation
| BP34 | #Pacientesnocontrole (patients in control): Campaign to increase access to metastatic breast cancer (mbc) treatment in Brazil. Maira Caleffi, BR | ||
| PO66 | Adverse events (AE) of targeted agents added to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Matteo Lambertini, BE | ||
| BP67 | Characteristics of the metastatic breast cancer population with PIK3CA mutation in the randomized phase II study SAFIR02 breast (UCBG- 0105/1304). Claudia Lefeuvre-Plesse, FR | ||
| PO36 | Fostering innovation in advocacy for metastatic breast cancer. Marina Teahon, CH | ||
| PO37 | Public hearings and debate cycles for parliamentarians on breast cancer. Maira Caleffi, BR | ||
| PO38 | A study of nursing provision and models of care for people diagnosed and living with metastatic breast cancer in Britain: what are the implications for the practice? and what role does patient advocacy play? Catherine Priestley, UK | ||
| PO39 | Educate-empower-advocate: A new model for advocacy and creating change for women with metastatic breast cancer. MJ DeCoteau, CA | ||
| PO40 | Patient navigation: Mitigating the surge of advanced breast cancer in sub-Saharan Africa. Runcie Chikeruba Wilson Chidebe, NG | ||
| PO41 | BC III and IV treatment in Brazil: Differences between public health, supplementary health and iternational protocol recommendations. Maira Caleffi, BR | ||
| PO42 | The unmet information, support and financial needs of women with metastatic breast cancer in Australia: results of two breast cancer network Australia studies. Danielle Spence, AU | ||
| PO43 | Tanto por hacer. Eliza Puente, MX | ||
| PO44 | Social media storytelling as an advocacy and support tool for people living with metastatic breast cancer. Janine Guglielmino, US | ||
| PO45 | Breast cancer knowledge and quality of life among participants of a breast cancer support group in rural Ruwanda. Thomas Albert Ndaysaba, RW | ||
| PO46 | Building a voice for metastatic breast cancer patients through a multi-year awareness campaign. Craig Faucette, CA | ||
| PO47 | Creating a novel drug navigation tool for metastatic breast cancer drugs in Canada. Craig Faucette, CA | ||
| PO48 | Share decision making for better patient participation in advanced breast cancer care. Marga Schrieks, NL | ||
| PO50 | Coping with metastatic breast cancer: the patients’ perspective in a Brazilian cancer center. Maira Caleffi, BR | ||
| PO51 | Clinical study to improve patient-hcp communication & engagement for newly diagnosed metastatic breast cancer patients. Corrine Ellsworth Beaumont, US | ||
| PO53 | No lump required: a patient driven inflammatory breast cancer reserach initiative using the peer platform. Ginny Mason, US | ||
| PO54 | The world is not enough: the twilight of MBC patients’ needs. Rania Azmi, KW | ||
| PO57 | Mesenchymal circulating tumour cell analysis to predict efficacy of eribulin for metastatic breast cancer patients. Yoshiya Horimoto, JP | ||
| PO58 | Regulation of stemness properties by ganoderma lucidum extract in inflammatory breast cancer cells via STAT3 regulation. Michelle Martinez Montemayor, PR | ||
| PO59 | IL-2 mediated improvement of cell antitumor activity in advanced breast cancer patients. Sandra Radenkovic, RS | ||
| PO60 | Influence of lipophilic components of matcha-tea extract on PPAR γ dependent cell proliferation. Lennard Schröder, DE | ||
| PO61 | The identification of the genes concerning to the distant metastasis of TNBC - the interaction with AR as an index. Noriko Miwa, JP | ||
| PO63 | Cancer associated fibroblasts display phenotypic and functional features that resemble circulating fibrocytes with constitute a nove subset of MDSCs. Gurcan Gunaydin, TR | ||
| PO68 | First-line ribociclib plus letrozole for postmenopausal women with HR+, HER2-ABC: MANALEESA-2 safety results. Pierfranco Conte, IT | ||
| PO69 | Overall survival and patient-reported impairment by fatigue, pain and treatment time in patients with advanced breast cancer in routine practice - results from the prospective German TMK cohort study. Norbert Marschner, DE | ||
| PO70 | Herceptin alone in comparison with herceptin combined evorilimus in Asian patients with HER2+ breast cancer. Farrukh Djuraev, UZ | ||
| PO71 | ERBB2 amplification level and PTPN2 gain as potential prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab. Sander Ellegard, SE | ||
| PO72 | Triplet combination of endocrine therapy with CDK 4/6 inhibitor, ribociclib, and mTOR inhibitor, everolimus in HR+, HER2-ABC: results from the dose-expansion cohort. Aditya Bardia, US | ||
| PO73 | Efficacy and safety of palbociclib (PAL) pus fulvestrant (F) by geographic region in women with endocrine-resistant hormone receptor-positive (HR+), human epiderman growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) from PALOMA-3. Nadia Harbeck, DE | ||
| PO74 | Efficacy and safety of platinum and metronomic cyclophosphamide in triple negative breast cancer. Giulia Viale, IT | ||
| PO75 | Retrospective analysis of advanced luminal breast cancer patients treated with endocrine therapy (ET) and palbociclib within a compassionate use programme. Christian Maurer, BE | ||
| PO76 | Preliminary data from a prospective non-interventional study to characterize real-world treatment patterns and outcomes of women with ER +/HER2-advanced/ metastatic breast cancer. Nadia Harbeck, DE | ||
| PO77 | Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): When care objectives meet patients’ need preliminary results of the VICTOR-6 study. Marina Elena Cazzaniga, IT | ||
| PO78 | Randomized prospective study: Paclitaxel every-3-weekly paclitaxel and versus weekly vinorelbine in metastatic breast cancer. Lika Katselashvili, GE | ||
| PO79 | Real world prescription patterns in metastatic HR+ breast cancer. Analysis from Instituto Nacional de Cancerologia, Mexico City. Claudia Arce Salinas, MX | ||
| PO80 | Efficacy of first line regimens in metastatic breast cancer patients. Real world evidence from Instituto Nacional de Cancerologia, Mexico City. Maria Tereza Nieto-Coronel, MX | ||
| PO81 | Ribociclib and endocrine therapy (ET) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER-2) breast cancer: The MONALEESA clinical trials program. Pierfranco Conte, IT | ||
| PO82 | A phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive HR+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy - vinometro. Christoph Thomssen, DE | ||
| PO83 | Prognostic factors in metastatic breast cancer patients to brain: retrospective analysis brain: retrospective analysis. Ahmed Gaballah, EG | ||
| PO84 | Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): Focus on luminal cancers. Results from GIM13-AMBRA study. Marina Elena Cazzaniga, IT | ||
| PO85 | Capecitabine and vinorelbine combination more effective as the first line treatment of advanced ER positive breast cancer. Loay Kassem, EG | ||
| PO86 | Efficacy and toxicity of eribulin in real-life non-selected advanced breast cancer patients. Anne Sofie Brems-Eskildsen, DK | ||
| PO87 | All oral combination of vinorelbine and capecitabile as a first line treatment in patients (pts) with metastatic breast cancer (MBC). Samir Shehata, EG | ||
| PO88 | Efficacy of capecitabile monotherapy as treatment for real life patients with HER2-negative mestastatic breast cancer. Anne Sofie Brems Eskildsen, DK | ||
| PO90 | Efficacy and safety of eribulin in combination with trastuzimab in HER2-positive metastatic breast cancer patients: real life experience. Elena Kovalenko, RU | ||
| PO91 | Relapse and metastatic spread patterns in patients with HER2/neu positive breast cancer who underwent targeted therapy. Ekaterine Arkania, GE | ||
| PO92 | Evaluation of pertuzumab treatment for metastatic breast cancer in a retrospective single institution study. Mitsugu Yamamoto, JP | ||
| PO93 | Leptomeningeal metastases from breast cancer - are we overtreatening? decision algorithms and assuring breast care. Ana Leonor Matos, PT | ||
| PO94 | Treatment of advanced breast cancer with T-DM1 in a cancer center. Filipa Ferreira Pereira, PT | ||
| PO95 | Patterns of response to therapy in ER/PR positive metastatic breast cancer. Marie Sundquist, SE | ||
| PO96 | Advanced breast cancer in young women: outcome of a Portuguese hospital. David da Silva Dias, PT | ||
| PO100 | Gastrointestinal and other selected adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: A systematic review and meta-analysis. Kyrillus Shohdy, EG | ||
| PO112 | Breast cancer liver metastases - when to operate. Vítor Devezas, PT | ||
| PO113 | GISEL study group proposal: a phase II randomized clinical trial in breast cancer patients with skin metastases treated with or without electrochemotherapy (ECT) during the first line of treatment. Roberto Agresti, IT | ||
| PO114 | Metastatic breast cancer patients who achieved clinical complete response after multidisciplinary therapy: clinical features from a single institution. Haruko Takuwa, JP | ||
| PO115 | A novel and innovative "non-tunneling" technique of port insertion for chemotherapy infusion in advance breast cancer patients: a single center study in 130 patients. Abhinav Deshpande, IN | ||
| PO117 | Electrochemoterapy (ECT) treatment in-patient with bone foot metastasis from breast: A case report. Daniele Screpis, IT | ||
| PO118 | Five years overall survival of locally advanced triple-negative breast cancer in west Sumatera, Indonesia. Daan Khambri, IN | ||
| PO121 | A retrospective cohort study to investigate association between preferences for future care and period of final chemotherapy administration before end-of-life. Sena Yamamoto, JP | ||
| PO122 | Advanced stage breast cancer lifestyle and exercise (ABLE) feasibility study: Preliminary results. Lidia Delrieu, FR | ||
| PO123 | Leaving a legacy: Half day retreat for young women living with metastatic breast cancer. Mary Ajango, US | ||
| PO125 | The information and support needs of women with metastatic breast cancer who have dependant aged children: A study to inform service development to support women talk with and prepare their children. Maria Leadbeater, UK | ||
| PO126 | Quality of life and psychosocial need of metastatic breast cancer patients. Tahir Mehmood, PK | ||
| PO127 | Palliative care in Egypt: Challenges and opportunities. Mohamed Hablas, EG | ||
| PO128 | G-CSF and G-CSF biosimilars: A meta-analysis of randomized clinical trials in breast cancer patients undergoing myelosuppressive chemotherapy. Giuseppe Curigliano, IT | ||
| PO129 | Musculoskeletal pain and health-related quality of life among breast cancer patients: Evidence from south India. Asmin Sha, IN | ||
| PO130 | Utilization of integrative supportive services in a specialized advanced breast cancer center. Timothy J. Pluard, US | ||
| PO131 | Predictive factors for persistent pain in patients with advanced breast cancer receiving adjuvant therapy. Teodora Alexa-Stratulat, RO | ||
| PO132 | Evaluation of health-related quality of life via the computer-based health evaluation system (CHES) for Japanese metastatic breast cancer patients: A single-center pilot study. Yuichiro Kikawa, JP | ||
| PO133 | Exploring support networks and quality of life of metastatic breast cancer patient in Nigeria and Turkey. Runcie Chikeruba Wilson Chidebe, NG | ||
| PO134 | Homestatic correlations in patients with breast and ovarian cancer. Elina Beleva, BG | ||
| PO136 | First-line treatment modality for metastatic breast cancer: A single-institution outcome analysis by metastatic site and molecular type. Russell Burcombe, UK | ||
| PO137 | Presentation and specific risk factors of inflammatory breast cancer (IBC): a multicenter Tunisian study. Nesrine Mejri Turki, TU | ||
| PO138 | Preference of treatment decision-making in women with advanced breast cancer. Chikako Shimizu, JP | ||
| PO139 | An investigation into the psycho-social benefits of women attending UK charity breast cancer care’s "living with secondary breast cancer" service: A group based psycho-educational intervention. Catherine Priestley, UK | ||
| PO140 | Rise of metastatic breast cancer incidence in Lebanon: Effect of refugees and displaced people from Syria, and patients from war-torn Iraq. Nagi S. El Saghir, LB | ||
| PO141 | Adjuvant therapies for breast cancer improve cure rates but appear to shorten post-metastatic survival. Nadia Harbeck, DE | ||
| PO142 | Advanced breast cancer prevalence and related personal factors. Nanuli Ninashvili, GE | ||
| PO143 | Inflammatory breast cancer: A single center experience from developing country. Pooja Khullar, IN | ||
| PO144 | Clinicopathological characteristics, prognosis and issues in young women (<40 years old) with recurrent or metastatic breast cancer. Kaori Ushimado, JP | ||
| PO145 | Harvesting population data to aid treatment decisions in heavily pre-treated advanced breast cancer. Sharon Hensley Alford, US |